Brief: Ikoniscope20 Preliminary Results Surpass Standards Of Test In Immuno-Oncology

Ikonisys SA

16/02/2022 18:30

Feb 16 (Reuters) - Ikonisys SA  ALIKO.PA :
    * IKONISYS: IKONISCOPE20 PRELIMINARY RESULTS OBTAINED WITH
UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE (NEAG CANCER CENTER
OF UCONN) IN DETECTING RARE CELLS SURPASS STANDARDS OF TEST IN
IMMUNO-ONCOLOGY
    * IKONISCOPE20 PRELIMINARY RESULTS OBTAINED WITH UNIVERSITY
OF
CONNECTICUT SCHOOL OF MEDICINE (NEAG CANCER CENTER OF UCONN) IN
DETECTING RARE CELLS SURPASS STANDARDS OF TEST IN
IMMUNO-ONCOLOGY
    * IKONISCOPE20 PERFORMS IMMUNE MONITORING FUNCTIONS MORE
EFFECTIVELY, EASILY AND COMPETITIVELY THAN CONVENTIONAL FLOW
CYTOMETERS (STANDARD TOOL USED FOR SUCH DETECTION)
    * IKONISCOPE20 DETECTS RARE CELLS AT A SUPERIOR RATE TO THAT
PROVIDED BY FLOW CYTOMETERS, ALSO PROVIDING DETAILED MORPHOLOGY
INFORMATION THANKS TO ITS HIGH-QUALITY IMAGES
    * MONITORING OF IMMUNE RESPONSES IN CANCER PATIENTS IS AN
INCREASING NEED BECAUSE OF NEWLY APPROVED IMMUNOTHERAPY
TREATMENTS
    * THOSE RESULTS PAVE WAY FOR NEW OPPORTUNITIES FOR
COMMERCIALIZATION OF IKONISCOPE20, AS A BETTER ALTERNATIVE THAN
FLOW CYTOMETER
    * THESE RESULTS OPEN NEW MARKET OPPORTUNITY FOR IKONISCOPE20
AS
INSTRUMENT OF CHOICE, FOR RESEARCH LABORATORIES DEDICATED TO
IMMUNO-ONCOLOGY, IN ADDITION TO BEING INSTRUMENT OF DISCOVERY IN
FIELD OF CIRCULATING TUMOR CELLS - CHIEF SCIENTIFIC OFFICER OF
IKONISYS

Source text for Eikon:  ID:nBw7vX9H4a 
Further company coverage:  ALIKO.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48587696600;))